23andMe Has Abandoned The Genetic Testing Tech Its Competition Is Banking On
By Stephanie M. Lee,
BuzzFeed
| 10. 26. 2016
Genetics startup 23andMe has let go of a team of scientists and a top executive as it has stopped pursuing one of the biggest technological advancements in DNA testing, BuzzFeed News has learned.
For years, genetic-testing startup 23andMe was working to develop a cutting-edge technology that could dramatically expand what its customers might learn about their DNA. While the company’s core product, a $199 “spit kit,” can tell you about your health and ancestry based on small bits of your genetic code, tests based on the new technology — called next-generation sequencing — could provide much more comprehensive information, including your potential risks for many diseases.
But 23andMe has given up on the technology for now, BuzzFeed News has learned.
Other companies are starting to sell next-generation sequencing-based tests to the public, and the FDA considers it to be the next chapter in genetic testing. But in August, 23andMe let go of its team of roughly a half-dozen scientists who were working on next-generation sequencing in a lab in Salt Lake City, Utah. Chief medical officer Jill Hagenkord, who was...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
